Expanding Global Access to Wockhardt's Breakthrough Antibiotic Zaynich A strategic collaboration proposal from GNH to bring life-saving innovation to patients worldwide
CRITICAL CHALLENGE The Urgent Global Challenge
Antimicrobial Resistance Antimicrobial resistance (AMR) represents one of the most pressing threats to global health today. Each year, approximately 5 million deaths occur worldwide due to drug-resistant infections, with multidrug-resistant gram- negative bacteria emerging as particularly deadly adversaries. As traditional antibiotics lose their effectiveness at an alarming rate, healthcare systems face a critical shortage of viable treatment options. This growing crisis demands breakthrough innovations that can effectively combat resistant pathogens and save lives. Zaynich addresses this urgent unmet medical need with demonstrated breakthrough efficacy against the most challenging resistant bacteria. 5M Annual Deaths Lives lost to AMR globally each year 100% Rising Threat Multidrug-resistant infections increasing sharply
BREAKTHROUGH INNOVATION Zaynich
A Game-Changing Antibiotic Innovation 14+ Years of Development India's first fully in-house novel antibiotic specifically engineered to combat drug-resistant gram- negative bacteria. Developed by Wockhardt through rigorous research and innovation. Exceptional Clinical Results Phase III trials demonstrated 96.83 98% efficacy rates, significantly outperforming standard treatments like meropenem in head-to-head comparisons. Perfect Cure Rates Achieved 100% cure rates across critical infection types including bloodstream infections, ventilator- associated pneumonia, and intra- abdominal infections.
REGULATORY EXCELLENCE Proven Regulatory Progress & Market Readiness
- US FDA Acceptance New Drug Application (NDA) accepted in late 2025, with potential Fast Track and QIDP designations offering extended market exclusivity and accelerated review pathways.
- Global Filings Regulatory submissions underway for Europe, India, and key emerging markets, positioning Zaynich for coordinated launches between 2025-2027.
- Manufacturing Excellence Production outsourced to European facilities ensuring full regulatory compliance, quality standards, and streamlined global supply chain capabilities.
Massive Market Opportunity & Impact Potential Global Market Landscape The global antibiotics market represents a substantial and growing opportunity, valued at $50353 billion in 2023-24 and projected to reach $68386 billion by 2030. This growth is driven by rising infection rates, increasing AMR prevalence, and urgent demand for novel therapeutic solutions. $8B Zaynich Addressable Market US and Europe combined potential $2B India Market Opportunity ¹17,000 crore potential value Patient Impact Scale $0.00 $30,000,000,000.00 $60,000,000,000.00 $90,000,000,000.00 Global 2024 Global 2030 Zaynich Target India Potential In India alone, Zaynich can treat over 1.1 million cases annually, addressing a massive unmet need in both hospital and community settings.
GLOBAL EXPERTISE GNH's Proven Global Access Frameworks Extensive Global Reach GNH has successfully scaled innovative health solutions across numerous countries through strategic partnerships with governments, NGOs, multilateral organizations, and healthcare providers, ensuring broad access and impact. Regulatory & Market Navigation Deep expertise in navigating complex regulatory requirements, reimbursement frameworks, and distribution challenges across diverse markets with varying healthcare systems and economic conditions. Accelerated Access Track Record Proven ability to accelerate patient access to breakthrough therapies while ensuring affordability, sustainable supply chains, and local capacity building for long-term impact.
PARTNERSHIP PROPOSAL Collaboration Proposal
Unlocking Zaynich's Global Reach Strategic Partnership GNH partners with Wockhardt to dramatically expand Zaynich's geographic footprint beyond current launch plans, targeting high-priority markets with significant AMR burden. Market Entry Facilitation Leverage GNH's established global networks to facilitate licensing agreements, regulatory registrations, and rapid market entry in priority countries across Asia, Africa, and Latin America. Optimized Market Strategy Joint efforts to develop optimal pricing strategies, forge local manufacturing partnerships, and drive healthcare provider engagement for maximum adoption and patient impact.
Strategic Benefits for Wockhardt & GNH Accelerated Market Access Rapid entry into high-value markets with significantly reduced commercial risk through GNH's proven frameworks and established relationships. Global Brand Leadership Enhanced international recognition as a pioneer in novel antibiotic development, positioning both organizations at the forefront of the AMR solution. Public Health Impact Meaningful contribution to global health by combating antimicrobial resistance and saving millions of lives at scale across underserved populations. Shared Expertise & Returns Combined innovation capabilities and market expertise to maximize both patient impact and commercial returns through complementary strengths.
ACTION PLAN Next Steps
Partnership Roadmap 01 Form Joint Task Force Immediate establishment of a dedicated team to identify target countries, assess market readiness, and map optimal regulatory pathways for rapid market entry. 02 Develop Market Access Plans Create tailored country-specific strategies leveraging GNH's access frameworks and Wockhardt's robust clinical data to address local needs and requirements. 03 Launch Pilot Collaborations Initiate pilot programs in carefully selected regions with high AMR burden and critical unmet medical need to validate approach and refine strategy. 04 Establish Success Metrics Define clear performance indicators and develop scalable rollout strategy for systematic expansion through 2026-2028, ensuring measurable impact and continuous improvement.
Together, We Can Defeat Drug- Resistant Infections Globally Join us in expanding access to Zaynich 4 a breakthrough antibiotic innovation with the power to save millions of lives worldwide. Let's collaborate to transform global health and combat antimicrobial resistance at scale. Partner With Us Learn More About Zaynich